Next Article in Journal
Overcharging Effect in Electrospray Ionization Mass Spectra of Daunomycin-Tuftsin Bioconjugates
Next Article in Special Issue
A Single-Turnover Kinetic Study of DNA Demethylation Catalyzed by Fe(II)/α-Ketoglutarate-Dependent Dioxygenase AlkB
Previous Article in Journal
New Sesquiterpenoids from the Fermented Broth of Termitomyces albuminosus and Their Anti-Acetylcholinesterase Activity
Review

Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs)

Departamento de Química y Bioquímica, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Alcorcón, 28925 Madrid, Spain
*
Authors to whom correspondence should be addressed.
Academic Editor: Sérgio F. Sousa
Molecules 2019, 24(16), 2982; https://doi.org/10.3390/molecules24162982
Received: 25 July 2019 / Revised: 12 August 2019 / Accepted: 13 August 2019 / Published: 16 August 2019
(This article belongs to the Special Issue Structure and Function of Metalloenzymes)
Matrix metalloproteinases (MMPs) are a family of zinc- and calcium-dependent endopeptidases which are secreted or anchored in the cell membrane and are capable of degrading the multiple components of the extracellular matrix (ECM). MMPs are frequently overexpressed or highly activated in numerous human diseases. Owing to the important role of MMPs in human diseases, many MMP inhibitors (MMPIs) have been developed as novel therapeutics, and some of them have entered clinical trials. However, so far, only one MMPI (doxycycline) has been approved by the FDA. Therefore, the evaluation of the activity of a specific subset of MMPs in human diseases using clinically relevant imaging techniques would be a powerful tool for the early diagnosis and assessment of the efficacy of therapy. In recent years, numerous MMPIs labeled imaging agents have emerged. This article begins by providing an overview of the MMP subfamily and its structure and function. The latest advances in the design of subtype selective MMPIs and their biological evaluation are then summarized. Subsequently, the potential use of MMPI-labeled diagnostic agents in clinical imaging techniques are discussed, including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and optical imaging (OI). Finally, this article concludes with future perspectives and clinical utility. View Full-Text
Keywords: Matrix metalloproteinases (MMPs); positron emission tomography (PET); single-photon emission computed tomography (SPECT) and optical imaging (OI) Matrix metalloproteinases (MMPs); positron emission tomography (PET); single-photon emission computed tomography (SPECT) and optical imaging (OI)
Show Figures

Graphical abstract

MDPI and ACS Style

Rangasamy, L.; Di Geronimo, B.; Ortín, I.; Coderch, C.; Zapico, J.M.; Ramos, A.; de Pascual-Teresa, B. Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs). Molecules 2019, 24, 2982. https://doi.org/10.3390/molecules24162982

AMA Style

Rangasamy L, Di Geronimo B, Ortín I, Coderch C, Zapico JM, Ramos A, de Pascual-Teresa B. Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs). Molecules. 2019; 24(16):2982. https://doi.org/10.3390/molecules24162982

Chicago/Turabian Style

Rangasamy, Loganathan, Bruno Di Geronimo, Irene Ortín, Claire Coderch, José M. Zapico, Ana Ramos, and Beatriz de Pascual-Teresa. 2019. "Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs)" Molecules 24, no. 16: 2982. https://doi.org/10.3390/molecules24162982

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop